Ishita Drugs and Industries Limited reported a net profit of ₹23.02 lakh for the quarter ended June 30, 2026, marking a decline from the ₹30.23 lakh earned in the same period of the previous year. The Ahmedabad-based pharmaceutical company’s revenue from operations fell sharply to ₹314.53 lakh in Q1FY26, compared to ₹540.05 lakh in Q1FY25. This contraction in top-line growth was the primary driver behind the lower profitability, despite a reduction in cost of material consumed. The Board of Directors approved the unaudited financial results on August 8, 2026, following a limited review by statutory auditors Jaymin Shah & Associates.

Beyond financial performance, the Board addressed key governance and operational matters during its meeting on August 8, 2026. The Board approved the re-appointment of Mrs. Abha Agrawal (DIN 01589479) as a Non-Executive Non-Independent Director, notwithstanding her attaining the age of 75 years. Her re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. Additionally, based on recommendations from the Audit Committee and the Nomination and Remuneration Committee, the Board accepted the revised remuneration proposal for Mr. Sumit Agrawal, Chief Financial Officer.

The company is currently undertaking significant infrastructure upgrades to comply with Revised Schedule M regulations for its manufacturing facilities. Managing Director Jagdish Agrawal informed the Board that construction of a new block for warehouse accommodation has been completed, while civil work for extending existing buildings is ongoing. To date, Ishita Drugs has spent nearly ₹435 lakh on renovating existing buildings and constructing new blocks. Furthermore, capital contracts and orders worth approximately ₹565 lakh have been issued for various utilities and equipment. The company is actively negotiating with banks to raise funds to finance this upgradation project.

Financial Performance Breakdown

The financial results for Q1FY26 reflect a challenging period compared to the prior year, although there was a slight improvement over the immediately preceding quarter (Q4FY26). Total income stood at ₹318.16 lakh, down from ₹549.16 lakh in Q1FY25. Cost of material consumed decreased substantially to ₹138.45 lakh from ₹379.59 lakh in the previous year’s corresponding quarter, indicating better input cost management or lower production volumes. However, this saving was offset by the steep drop in revenue. Other income also contracted to ₹3.63 lakh from ₹9.11 lakh year-on-year.

What the Numbers Show

A notable divergence exists between revenue trends and expense management in Q1FY26. While revenue dropped by approximately 42% year-on-year, total expenses fell by roughly 43%, demonstrating effective cost control during a period of lower sales volume. Specifically, finance costs reduced to ₹0.47 lakh from ₹2.33 lakh in Q1FY25, contributing positively to the bottom line. However, other expenses remained relatively sticky at ₹72.70 lakh, only slightly higher than the ₹66.83 lakh recorded in Q1FY25, suggesting fixed overheads are not scaling down proportionally with revenue. The debt-equity ratio remains at 0.00, indicating a debt-free balance sheet, which provides flexibility for the planned facility upgrades without immediate pressure on interest servicing.

Ishita Pharmaceuticals, a related party of ishita drugs & indus , acquired 223 equity shares of ₹10 each through an open market transaction on June 22, 2026. This acquisition increases the acquirer's holding in the pharmaceutical manufacturer to 1.10% of the total paid-up share capital. The transaction was disclosed to BSE Limited on June 24, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Acquisition Details

The disclosure confirms that Ishita Pharmaceuticals purchased 223 shares carrying voting rights. Prior to this acquisition, the acquirer held 32,697 shares, representing 1.09% of the total share capital. The latest purchase brings the total holding to 32,920 shares. The equity share capital of Ishita Drugs and Industries Limited remains at ₹29,903,000, comprising 2,990,300 shares of ₹10 each.

Holding Structure

The filing details the acquirer's position before and after the transaction. There were no changes in encumbrances, voting rights held otherwise than by shares, or holdings in warrants and convertible securities. The entire acquisition consisted of shares carrying voting rights.

Regulatory Filing

The disclosure was submitted to BSE Limited, where Ishita Drugs and Industries Limited is listed under scrip code 524400. Ishita Pharmaceuticals is classified as a related party of the target company rather than a member of the promoter or promoter group. The transaction was executed on June 22, 2026, and the necessary disclosures were filed on June 24, 2026, to comply with SEBI regulations.